Stay updated on Risankizumab Dose Regimens in Japanese GPP/EP Clinical Trial

Sign up to get notified when there's something new on the Risankizumab Dose Regimens in Japanese GPP/EP Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Risankizumab Dose Regimens in Japanese GPP/EP Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:41:33.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the safety and efficacy data of two different dose regimens of risankizumab for Japanese subjects with generalized pustular psoriasis or erythrodermic psoriasis up to December 14, 2017.
    Difference
    0.1%
    Check dated 2024-06-06T14:32:33.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying the inclusion and exclusion criteria for individuals with Generalized Pustular Psoriasis (GPP) and Erythrodermic Psoriasis (EP). Previously, this section had no information provided.
    Difference
    22%
    Check dated 2024-05-22T21:36:51.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:36:49.000Z thumbnail image

Stay in the know with updates to Risankizumab Dose Regimens in Japanese GPP/EP Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Risankizumab Dose Regimens in Japanese GPP/EP Clinical Trial page.